FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula I wherein W is -CH2CH2-； X is N or CR6； R1 is selected from 5-6 membered heteroaryl, unsubstituted or substituted with 1 to 3 substituents, wherein said heteroaryl contains from 1 to 2 heteroatoms selected from a sulphur or nitrogen atom, and each of said substituents is independently selected from a halogen atom, straight or branched C1-C4 alkyl, straight or branched C1-C4 alkoxy, -NR10R11, -C(=O)R12, straight or branched C1-C4 alkanoyloxy, cyano, nitro, or two adjacent substituents together with the attached carbon atom form a 6-membered aromatic ring, a 5-membered saturated ring or a 5-membered heterocyclic ring containing 2 heteroatoms selected from an oxygen atom； R2 is selected from the following groups, unsubstituted or substituted with 1 to 3 substituents: straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, a 6-membered heterocyclic group containing 1 heteroatom selected from a nitrogen atom, C6-aryl； wherein said substituent is selected from the group consisting of a halogen atom, straight or branched C1-C4 alkyl, straight or branched C1-C4 alkylsulphonyl group, tetrazolyl, cyano； each of R3, R4 and R5 is independently selected from the group consisting of H, straight or branched C1-C6 alkyl； values of other radicals are given in the patent claim. Invention also relates to a production method, a pharmaceutical composition and to the use of the compound. .EFFECT: technical result: obtaining novel compounds of formula I, which have the properties of a CCR5 antagonist and can be used to treat human immunodeficiency virus (HIV) infection.10 cl, 13 tbl, 181 exИзобретение относится к соединению формулы I, в которой W представляет собой -СН2СН2-； X представляет собой N или CR6； R1 выбран из 5-6-членного гетероарила, незамещенного или замещенного от 1 до 3 заместителями, где указанный гетероарил содержит от 1 до 2 гетероатомов, выбранных из атома серы или азота, и каждый из указанных заместителе
